The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference demonstrate why optimal treatment of Alzheimer’s will require drugs that do more than clear amyloid plaques, says the Alzheimer’s Drug Discovery Foundation (ADDF).
FDA approves first gene therapy for hemophilia B
Cell & Gene Therapies
Fujifilm invests $188m in new North Carolina cell culture media facility
Cell & Gene Therapies
CGT Catapult: Developing and growing UK advanced therapies workforce is key priority
Cell & Gene Therapies
NextCure and LegoChem Biosciences team up to develop antibody drug conjugates
Antibody-Drug Conjugates
